Dashboard
High Management Efficiency with a high ROE of 14.35%
Strong ability to service debt as the company has a low Debt to EBITDA ratio of 0.73 times
Healthy long term growth as Net Sales has grown by an annual rate of 25.12% and Operating profit at 96.36%
The company has declared Negative results for the last 5 consecutive quarters
With ROE of 9.05%, it has a attractive valuation with a 4.24 Price to Book Value
Stock DNA
Pharmaceuticals & Biotechnology
USD 6,967 Million (Small Cap)
47.00
NA
0.00%
0.22
8.32%
4.25
Total Returns (Price + Dividend) 
Stevanato Group SpA for the last several years.
Risk Adjusted Returns v/s 
News

Stevanato Group SpA Experiences Revision in Its Stock Evaluation Amid Market Dynamics
Stevanato Group SpA, a small-cap in the Pharmaceuticals & Biotechnology sector, has recently adjusted its valuation metrics, including a P/E ratio of 47 and a price-to-book value of 4.24. The company’s stock performance has fluctuated, with a 6.07% return over the past year, reflecting competitive dynamics within the industry.
Read MoreIs Stevanato Group SpA technically bullish or bearish?
As of 31 October 2025, the technical trend for Stevanato Group SpA has changed from bullish to mildly bullish. The weekly MACD is mildly bearish, while the monthly MACD remains bullish, indicating mixed signals. The daily moving averages are mildly bullish, but the weekly KST is also mildly bearish. Overall, the indicators suggest a cautious bullish stance. In terms of performance, the stock has underperformed the S&P 500 over the past week and month, both down 4.77% compared to the S&P's gains of 0.71% and 1.92%, respectively. However, it has outperformed the S&P 500 year-to-date and over the past year, with returns of 13.54% and 26.29% compared to the S&P's 16.30% and 19.89%....
Read More
Stevanato Group SpA Experiences Revision in Stock Evaluation Amid Market Dynamics
Stevanato Group SpA, a small-cap in the Pharmaceuticals & Biotechnology sector, has seen its stock price adjust to $24.68. The company has experienced varying performance metrics, with a year-to-date return of 13.26%, trailing the S&P 500, but outperforming it over the past year and three years.
Read More Announcements 
Corporate Actions 
Quality key factors 
Valuation key factors
Technicals key factors
Shareholding Snapshot : Mar 2025
Shareholding Compare (%holding) 
Domestic Funds
Held in 51 Schemes (54.26%)
Held by 77 Foreign Institutions (21.15%)
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
YoY Growth in quarter ended Jun 2025 is 13.71% vs 0.54% in Jun 2024
YoY Growth in quarter ended Jun 2025 is 51.80% vs -40.48% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
YoY Growth in year ended Dec 2024 is 1.77% vs 13.50% in Dec 2023
YoY Growth in year ended Dec 2024 is -19.11% vs 4.79% in Dec 2023






